Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170

Alison M. Dunning, Kyriaki Michailidou, Karoline B. Kuchenbaecker, Deborah Thompson, Juliet D. French, Jonathan Beesley, Catherine S. Healey, Siddhartha Kar, Karen A. Pooley, Elena Lopez-Knowles, Ed Dicks, Daniel Barrowdale, Nicholas A. Sinnott-Armstrong, Richard C. Sallari, Kristine M. Hillman, Susanne Kaufmann, Haran Sivakumaran, Mahdi Moradi Marjaneh, Jason S. Lee, Margaret HillsMonika Jarosz, Suzie Drury, Sander Canisius, Manjeet K. Bolla, Joe Dennis, Qin Wang, John L. Hopper, Melissa C. Southey, Annegien Broeks, Marjanka K. Schmidt, Artitaya Lophatananon, Kenneth Muir, Matthias W. Beckmann, Peter A. Fasching, Isabel dos-Santos-Silva, Julian Peto, Elinor J. Sawyer, Ian Tomlinson, Barbara Burwinkel, Frederik Marme, Pascal Guenel, Therese Truong, Stig E. Bojesen, Henrik Flyger, Anna Gonzalez-Neira, Jose I. A. Perez, Arjen R. Mensenkamp, EMBRACE, GEMO Study Collaborators, HEBON, kConFab Investigators

OnderzoeksoutputAcademicpeer review

69 Citaten (Scopus)

Samenvatting

We analyzed 3,872 common genetic variants across the ESR1 locus (encoding estrogen receptor a) in 118,816 subjects from three international consortia. We found evidence for at least five independent causal variants, each associated with different phenotype sets, including estrogen receptor (ER+ or ER-) and human ERBB2 (HER2(+) or HER2(-)) tumor subtypes, mammographic density and tumor grade. The best candidate causal variants for ER-tumors lie in four separate enhancer elements, and their risk alleles reduce expression of ESR1, RMND1 and CCDC170, whereas the risk alleles of the strongest candidates for the remaining independent causal variant disrupt a silencer element and putatively increase ESR1 and RMND1 expression.

Originele taal-2English
Pagina's (van-tot)374-+
Aantal pagina's16
TijdschriftNature Genetics
Volume48
Nummer van het tijdschrift4
DOI's
StatusPublished - apr-2016

Citeer dit